ID
44154
Beschrijving
NCT02641314 Phase 2 Trial of Metronomic Treatment in Children and Adolescents With Recurrent or Progressive Neuroblastoma (NB). The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating immune response, ant-neuroblastic), cyclophosphamide (antiangiogenetic, anti-neuroblastic), etoposide (antiangiogenetic, anti-neuroblastic), and vinblastin (antiangiogenetic, anti-neuroblastic). Vinblastin is scheduled every 14 days intravenously, all other drugs are applied daily throughout 365 days (except etoposide for 4x3 weeks). The efficacies of each of the drugs have been demonstrated in vitro and in vivo in animal studies. All drugs have been used in children for other conditions. From those experiences low toxicities and a favorable Quality of life are expected. Prof. Dr. Frank Berthold Abt. für Kinderonkologie und –hämatologie Zentrum für Kinder- und Jugendmedizin Universität zu Köln
Trefwoorden
Versies (5)
- 26-12-17 26-12-17 -
- 27-12-17 27-12-17 -
- 15-03-21 15-03-21 - Dr. rer. medic Philipp Neuhaus
- 13-04-21 13-04-21 - Dr. rer. medic Philipp Neuhaus
- 20-09-21 20-09-21 -
Houder van rechten
Universität zu Köln
Geüploaded op
20 september 2021
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY-NC 3.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma (METRO-NB2012) NCT02641314
Study relevant visits
- StudyEvent: Subject Protocol
- Registration
- Medical history
- Baseline
- Therapy and toxicity cycle 1-3
- Therapy and toxicity cycle 4-6
- Therapy and toxicity cycle 7-9
- Therapy and toxicity cycle 10-13
- Therapy and toxicity cycle > 13
- Reference
- Study relevant visits
- Therapeutic response
- End of therapy
- Relapse
- Second malignancy
- Death
- Follow up
Beschrijving
Beurteilung der Lebensqualität
Beschrijving
Surrogatmarker
Beschrijving
undefined item
Datatype
boolean
Alias
- UMLS CUI [1]
- C0079611
Beschrijving
Collection of blood specimen for laboratory procedure Date in time
Datatype
date
Maateenheden
- mm/dd/yyyy
Alias
- UMLS CUI [1,1]
- C0178913
- UMLS CUI [1,2]
- C0011008
Beschrijving
Report sent?
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1524049
- UMLS CUI [1,2]
- C0520510
- UMLS CUI [1,3]
- C0008976
- UMLS CUI [1,4]
- C0205099
Beschrijving
biomarker
Datatype
boolean
Alias
- UMLS CUI [1]
- C0005516
Beschrijving
Date blood sample
Datatype
date
Maateenheden
- mm/dd/yyyy
Alias
- UMLS CUI [1,1]
- C0005834
- UMLS CUI [1,2]
- C0011008
Beschrijving
Specimen sent
Datatype
boolean
Alias
- UMLS CUI [1,1]
- C1524049
- UMLS CUI [1,2]
- C0008976
- UMLS CUI [1,3]
- C0205099
Beschrijving
Batch
Datatype
boolean
Alias
- UMLS CUI [1]
- C3641829
Beschrijving
Shipping date in time
Datatype
date
Maateenheden
- mm/dd/yyyy
Alias
- UMLS CUI [1,1]
- C0370003
- UMLS CUI [1,2]
- C1524049
- UMLS CUI [1,3]
- C0011008
Beschrijving
Bemerkung
Similar models
Study relevant visits
- StudyEvent: Subject Protocol
- Registration
- Medical history
- Baseline
- Therapy and toxicity cycle 1-3
- Therapy and toxicity cycle 4-6
- Therapy and toxicity cycle 7-9
- Therapy and toxicity cycle 10-13
- Therapy and toxicity cycle > 13
- Reference
- Study relevant visits
- Therapeutic response
- End of therapy
- Relapse
- Second malignancy
- Death
- Follow up
C0392360 (UMLS CUI [1,2])
C0034380 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0520510 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,3])
C0205099 (UMLS CUI [1,4])
C0011008 (UMLS CUI [1,2])
C0008976 (UMLS CUI [1,2])
C0205099 (UMLS CUI [1,3])
C1524049 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])